


Supplementary Figure 3



**Supplementary Figure 3 – HGSC and Fallopian Tube non-malignant cells respond differently to SMAP-061 alone and to combination strategies.** A) OV81, B) PEO-1 and C) PEO-C4.2 cells were treated with increasing doses of SMAP-061, cisplatin or combination of both to measure cell viability at 48 hours using MTT. D) Comparison of FT246 and OV81 responses to SMAP-061 utilizing MTT was performed. E) and F) FT246 cells were treated with increasing doses of SMAP-061, Olaparib, or combination of the two and cell viability after 48 hours were measured. Data presented as the mean  $\pm$  SD (n=3).